FcrR3A-158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment.
- Author:
Heejung CHAE
1
;
Changhoon YOO
;
Jung A YOON
;
Hee Jin LEE
;
Kyu Pyo KIM
;
Jeong Eun KIM
;
Jin Hee AHN
;
Kyung Hae JUNG
;
Gyungyub GONG
;
Sung Bae KIM
Author Information
- Publication Type:Original Article
- Keywords: Breast neoplasms; ErbB-2 receptor; Trastuzumab; Tumor infiltrating lymphocytes
- MeSH: Biopsy; Breast Neoplasms*; Breast*; Classification; Disease-Free Survival; Female; Genotype; Humans; Lymphocytes, Tumor-Infiltrating*; Prognosis; Real-Time Polymerase Chain Reaction; Receptor, Epidermal Growth Factor; Receptor, ErbB-2; Retrospective Studies; Trastuzumab
- From:Journal of Breast Cancer 2018;21(1):45-50
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The prognosis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer has markedly improved since the introduction of trastuzumab. We aimed to evaluate the association between stromal tumor-infiltrating lymphocyte (sTIL) or FcrR polymorphisms and survival among patients with metastatic HER2-positive breast cancer who were treated with trastuzumab. METHODS: A total of 56 women with recurrent or metastatic HER2-positive breast cancer who received the trastuzumab-taxane combination as first-line treatment were included in this retrospective analysis. The single-step multiplex allele-specific real-time polymerase chain reaction technique was employed for FcrR3A genotyping. sTILs were identified via immunohistochemical analysis of surgical (n=34, 60.7%) or biopsy specimens of metastatic lesions (n=22, 39.3%). RESULTS: We classified patients based on the sTIL level (≤10% [n=44] or >10% [n=12]); high sTIL counts were more commonly observed in patients with hormone receptor-negative tumors than in those with hormone receptor-positive tumors (34.8% vs. 12.1%, p=0.02). There was a significant association between high sTIL levels and longer progression-free survival in comparison to low sTIL levels (median, 28.4 months vs. 16.8 months; p=0.03). With regard to the FcrR3A-158 genotype, patients were classified into the Phenylalanine/Phenylalanine group (23 patients, 41.1%), Phenylalanine/Valine group (23 patients, 41,1%), or Valine/Valine group (10 patients, 17.9%); these classifications were not associated with clinical outcomes. CONCLUSION: High sTIL expression may be associated with better efficacy of trastuzumab-containing therapy in patients with metastatic HER2-positive breast cancer. However, this finding warrants further evaluation in the larger population.
